111 Capital Sells 28,807 Shares of Pfizer Inc. $PFE

111 Capital trimmed its position in Pfizer Inc. (NYSE:PFE) by 41.7% in the 2nd quarter, Holdings Channel reports. The firm owned 40,236 shares of the biopharmaceutical company’s stock after selling 28,807 shares during the quarter. 111 Capital’s holdings in Pfizer were worth $975,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Bessemer Group Inc. raised its position in shares of Pfizer by 11.1% during the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock valued at $3,358,000 after buying an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK raised its position in shares of Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock valued at $35,817,000 after buying an additional 17,032 shares in the last quarter. CHURCHILL MANAGEMENT Corp purchased a new stake in shares of Pfizer during the 1st quarter valued at $8,283,000. Westbourne Investments Inc. purchased a new stake in shares of Pfizer during the 1st quarter valued at $2,411,000. Finally, Bourne Lent Asset Management Inc. raised its position in shares of Pfizer by 90.8% during the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after buying an additional 18,200 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on PFE shares. Morgan Stanley raised their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Bank of America raised their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Saturday, September 27th. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Finally, Citigroup lifted their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $28.41.

Pfizer Price Performance

PFE stock opened at $27.37 on Friday. The firm’s 50-day moving average price is $24.67 and its two-hundred day moving average price is $24.14. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The stock has a market capitalization of $155.59 billion, a price-to-earnings ratio of 14.56, a PEG ratio of 0.88 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the previous year, the company earned $0.60 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.